wolbring

Archive for October 16th, 2006|Daily archive page

Graphic visualization of trends

In Uncategorized on October 16, 2006 at 2:50 am

Google tool
Gapminder

Nanosheets That Mimic Protein Formation Made By Researchers

In nano on October 16, 2006 at 2:34 am

How to direct and control the self-assembly of nanoparticles is a fundamental question in nanotechnology.

University of Michigan researchers have discovered a way to make nanocrystals in a fluid assemble into free-floating sheets the same way some protein structures form in living organisms.

“This establishes an important connection between two basic building blocks in biology and nanotechnology, that is, proteins and nanoparticles, and this is very exciting for assembling materials from the bottom up for a whole slew of applications ranging from drug delivery to energy,” said Sharon Glotzer, professor of chemical engineering and materials science and engineering.

Read more

Amyris Biotechnologies Synthetic Biology Pioneer Expands Into Bioenergy Field

In Uncategorized on October 16, 2006 at 2:29 am

Some excerpts from press release
EMERYVILLE, Calif., October 12, 2006 /PRNewswire/ — Amyris Biotechnologies, Inc., a privately-held company applying advances in synthetic biology to produce high-value pharmaceuticals, fine chemicals and biofuels, today announced that the company has raised $20 million in a first round of venture funding.

Mr. Melo stated, “I am excited about this opportunity to join a company that is using cutting-edge tools in chemistry and biology to develop solutions for major world problems, and look forward to guiding Amyris’ expansion into new areas, including polymers, specialty chemicals and nutraceuticals, in addition to biofuels.”

“The completion of this financing validates the strength of Amyris’ core technology and signals an important step in the company’s growth. These new resources will enable the company to expand its capabilities to address major global health and energy challenges, thereby helping to fulfill the promise of synthetic biology,” stated Jay D. Keasling, Ph.D., an Amyris founder, head of the company’s Scientific Advisory Board, and University of California, Berkeley, professor of chemical engineering and bioengineering. “In addition to its ongoing focus on creating a low-cost malaria drug, Amyris will add a new program aimed at renewably producing second-generation, high-performance biofuels with increased cost-effectiveness.”

Amyris Biotechnologies uses synthetic biology techniques to create new metabolic pathways in industrial microbes, turning them into living chemical factories for the efficient production of novel or rare chemicals. Amyris’ primary project to date has focused on the use of synthetic biology to address supply and cost constraints limiting the use of the life-saving anti-malarial drug, artemisinin.
Read the complete one

see also here
Amyris webpage